Nurse Practitioner Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Kathryn Wakeland

Registered Nurse, Emergency Fort Worth, TX Nurse Practitioner

NPI 1184342339 CMS profile 11383386

6844 Harris Pkwy Ste 300, Fort Worth, TX 76132

Open in the dashboard

General payments

$28,657

271 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kathryn Wakeland of Fort Worth, TX is reported in the CMS Open Payments database as having received $28,657 across 271 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $25,986 133
2024 General $2,123 109
2023 General $528 28
2022 General $20 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kathryn Wakeland
  • Registered Nurse, Emergency median
  • Middle half of Registered Nurse, Emergency
  • National median

In program year 2025, general payments to Kathryn Wakeland were reported at $25,986. Among 48 Registered Nurse, Emergency profiles paid that year, the median was $76 and the middle half received between $24 and $215.

Show as a table
Year Kathryn Wakeland Registered Nurse, Emergency median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $0 — — $132
2022 $20 $56 $19–$124 $149
2023 $528 — — $160
2024 $2,123 $78 $25–$107 $164
2025 $25,986 $76 $24–$215 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Insulet Corporation $23,490 24 payments
  2. Novo Nordisk Inc $729 39 payments
  3. Lilly USA, LLC $662 38 payments
  4. Dexcom, Inc. $443 20 payments
  5. Neurocrine Biosciences, Inc. $376 11 payments
  6. Xeris Pharmaceuticals, Inc. $358 15 payments
  7. Sanofi-Aventis U.S. LLC $277 10 payments
  8. Corcept Therapeutics $216 9 payments
  9. Tandem Diabetes Care, Inc. $187 11 payments
  10. Sequel Med Tech, LLC $180 9 payments
  11. Other $1,739 85 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $23,227 18 payments
  2. Food and Beverage $5,406 252 payments
  3. Education $24 1 payment
Products named General payments · program years 2022–2025
  1. Omnipod $23,490 24 payments
  2. Ozempic $526 30 payments
  3. Dexcom G6 Transmitter $443 20 payments
  4. MOUNJARO $370 21 payments
  5. CRENESSITY $343 10 payments
  6. RYBELSUS $261 19 payments
  7. ZEPBOUND $257 17 payments
  8. TZIELD $256 9 payments
  9. RECORLEV $251 10 payments
  10. Korlym $216 9 payments
  11. Other $2,620 130 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 28 drugs

Part D claims

1,144

Median for Registered Nurse: 109

Drug cost

$930,629

Median for Registered Nurse: $4,454

Branded share of claims

85.4%

Median for Registered Nurse: 15.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 211 $288,923
Ozempic Semaglutide Brand 99 $140,655
Jardiance Empagliflozin Brand 113 $126,296
Trulicity Dulaglutide Brand 67 $106,235
Toujeo Max Solostar Insulin Glargine,hum.Rec.Anlog Brand 24 $53,434
Tresiba Flextouch U-100 Insulin Degludec Brand 38 $47,608
Omnipod 5 Dexg7g6 Pods (Gen 5) Insulin Pump Cart,auto,bt,g6/7 Brand 44 $32,576
Synjardy Xr Empagliflozin/Metformin Hcl Brand 30 $28,317
Farxiga Dapagliflozin Propanediol Brand 13 $22,809
Toujeo Solostar Insulin Glargine,hum.Rec.Anlog Brand 20 $13,554

The 10 drugs with the highest cost, of 28 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 476 Part D prescribers listed as Registered Nurse; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 31 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Wegovy
  • Novo Nordisk Inc $182
$182 — —
MOUNJARO
  • Lilly USA, LLC $155
$155 211 —
TZIELD
  • SANOFI-AVENTIS U.S. LLC $125
$125 — —
Korlym
  • Corcept Therapeutics $122
$122 — —
TERIPARATIDE
  • Alvogen Inc $90
$90 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 31 with Patron

Records

271 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Registered Nurse, Emergency in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record